In a recent episode of The Genetics Podcast, Patrick spoke with Kent Rogers, CEO of EveryONE Medicines, about the future of individualized medicines, especially in ultra-rare diseases. With over 30 years in the pharmaceutical and healthcare sectors, spanning big pharma, payers, biotech, and venture capital, Kent shared how his experience has positioned him to take on one of medicine’s most urgent and complicated challenges: developing scalable treatments for conditions that affect only a handful of patients worldwide.
Precision medicine has the potential to transform how we understand and treat autoimmune and inflammatory diseases, but only if we can align innovation with infrastructure.
Here, we outline a strategic framework designed to help pharma and biotech leaders navigate the evolution of autoimmune and inflammatory disease treatment. From integrated data ecosystems and cross-disciplinary partnerships to smarter clinical trial design and equitable access models, we explore the foundational steps needed to bring precision medicine into real-world care for these complex immune conditions.
The way we treat autoimmune and inflammatory diseases is undergoing a fundamental shift. With advances in tools like CRISPR, single-cell analysis, and genetically engineered therapies, we’re entering an era where one-time treatments and long-term remission are no longer just goals, they’re real possibilities.
Podcast recap: Matt Burgess on genetic counseling, ethics in rare disease, and demystifying genetics
In the most recent episode of The Genetics Podcast, Patrick sits down with fellow podcaster and genetic counselor Matt Burgess. Matt is the host of Demystifying Genetics, a show that aims to make genetic science and counseling more approachable. Together, they explore Matt’s journey in clinical genetics, the changing role of genetic counselors, and the ethical issues around topics like gene therapy for ultra-rare conditions.
Treating autoimmune and inflammatory diseases has long relied on broad-spectrum drugs that suppress the immune systems. While these medications can be effective, they often act as blunt tools, leading to serious side effects such as increased risk of infections, long-term organ damage, and reduced quality of life. In this post, we explore how new therapies, from biologics and small molecule inhibitors to emerging CAR-T cell treatments, could be the future of treatment. We also examine the gaps still holding precision medicine back.
Despite growing momentum behind precision medicine, autoimmune and inflammatory diseases remain some of the most underserved areas in healthcare. Affecting an estimated 1 in 10 people globally, these conditions, from lupus and rheumatoid arthritis to Crohn’s disease and atopic dermatitis, are highly heterogeneous, notoriously complex, and often poorly understood at the molecular level.
In a recent episode of The Genetics Podcast, Patrick spoke with Dr. Sal Rico, Chief Medical Officer at Encoded Therapeutics. Having worked across small molecules, medical devices, and now gene therapy, Sal has spent the last decade improving treatments for severe neurological conditions, particularly in children.
Precision medicine offers more targeted treatments, better patient outcomes, and even the potential to transform how we approach disease. But getting there isn’t easy. For many companies, especially smaller ones, the costs of getting started are just too high. From the price of genomic sequencing to the investment needed for specialized tools and training, these upfront costs can feel like a major barrier. In this post, we take a closer look at the real cost challenges facing precision medicine today, and explore how long-term thinking, smarter investments, and clearer regulations could help make precision medicine more accessible to everyone.
When it comes to rare and ultra-rare diseases, finding the right data can be one of the biggest hurdles in research and drug development. With thousands of rare conditions affecting only a small number of people, the data needed to understand these diseases is often scattered, inconsistent, or hard to access. That’s why collaboration, smart technology, and a focus on patient trust are so important. Here, we take a closer look at how better data practices, from standardization to secure sharing, can help researchers, clinicians, and patients work together to move precision medicine forward.
As clinical trials become more complex and patient populations more diverse, the traditional focus on recruitment alone is no longer enough. Building long-term patient relationships grounded in trust, education, and collaboration, is increasingly recognized as essential to trial success. Here, we explore how a patient-centric approach can improve retention, enhance data quality, and ultimately accelerate the development of new treatments.